BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 1878719)

  • 1. Haemostatic changes in uncomplicated bone marrow transplants.
    Collins P; Jones B; Uthayakumar S; Pocock C; Jupp R; Gutteridge G; Chopra R; Blare S; Newland A
    Bone Marrow Transplant; 1991; 7 Suppl 2():54. PubMed ID: 1878719
    [No Abstract]   [Full Text] [Related]  

  • 2. Changes in protein C, factor VII and endothelial markers after autologous bone marrow transplantation: possible implications in the pathogenesis of veno-occlusive disease.
    Bazarbachi A; Scrobohaci ML; Gisselbrecht C; Marolleau JP; Mansi A; Brice P; Gorra P; Drouet L
    Nouv Rev Fr Hematol (1978); 1993 Apr; 35(2):135-40. PubMed ID: 8332449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: incidence, risk factors, and clinical outcome.
    Ozkaynak MF; Weinberg K; Kohn D; Sender L; Parkman R; Lenarsky C
    Bone Marrow Transplant; 1991 Jun; 7(6):467-74. PubMed ID: 1908340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation.
    Park YD; Yasui M; Yoshimoto T; Chayama K; Shimono T; Okamura T; Inoue M; Yumura-Yagi K; Kawa-Ha K
    Bone Marrow Transplant; 1997 May; 19(9):915-20. PubMed ID: 9156266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Whole body irradiation in the conditioning of bone marrow transplantation. Current indications and limiting factors].
    Ganem G; Cosset JM; Le Bourgeois JP
    Ann Med Interne (Paris); 1989; 140(5):387-92. PubMed ID: 2688510
    [No Abstract]   [Full Text] [Related]  

  • 6. Regimen-related acute toxicities: pathophysiology, risk factors, clinical evaluation and preventive strategies.
    Klingemann HG; Shepherd JD; Reece DE; Barnett MJ; Nantel SH; Sutherland HJ; Spinelli JJ; Phillips GL
    Bone Marrow Transplant; 1994; 14 Suppl 4():S14-8. PubMed ID: 7728119
    [No Abstract]   [Full Text] [Related]  

  • 7. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia.
    Jillella AP; Doria R; Khan K; Zelterman D; Ahmad YH; Smith BR; Holmes W; Becker P; Roberts KB; Rappeport JM
    Bone Marrow Transplant; 1999 Jun; 23(11):1095-100. PubMed ID: 10382947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Whole body irradiation].
    Le Bourgeois JP; Ganem G
    Pathol Biol (Paris); 1989 Feb; 37(2):156-8. PubMed ID: 2652070
    [No Abstract]   [Full Text] [Related]  

  • 9. Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2).
    Copelan EA; Biggs JC; Szer J; Thompson JM; Crilley P; Brodsky I; Klein JL; Kapoor N; Harman GS; Avalos BR
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):33-8; quiz 39. PubMed ID: 8342074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Veno-occlusive disease after bone marrow transplantation: preventive effect of heparin].
    Parquet N; Devergie A; Socié G; Ribaud P; Espérou H; Gluckman E
    Ann Med Interne (Paris); 1997; 148(2):132-5. PubMed ID: 9238437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial comparing busulfan vs total body irradiation in allogeneic marrow transplant recipients with hematological malignancies.
    Ringdén O; Ruutu T; Remberger M; Nikoskelainen J; Volin L; Vindeløv L; Parkkali T; Lenhoff S; Sallerfors B; Ljungman P
    Transplant Proc; 1994 Jun; 26(3):1831-2. PubMed ID: 8030160
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of chronic myelogenous leukemia with allogeneic bone marrow transplantation after preparation with busulfan and cyclophosphamide (BuCy2): an update.
    Brodsky I; Biggs JC; Szer J; Crilley P; Atkinson K; Downs K; Dodds A; Concannon AJ; Avalos BR; Tutschka P
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):27-31; quiz 32. PubMed ID: 8342072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers.
    Scrobohaci ML; Drouet L; Monem-Mansi A; Devergie A; Baudin B; D'Agay MF; Gluckman E
    Thromb Res; 1991 Sep; 63(5):509-19. PubMed ID: 1755004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between donor-recipient blood group incompatibility and serum bilirubin after allogeneic bone marrow transplantation from HLA-identical siblings.
    Mehta J; Powles R; Horton C; Milan S; Singhal S; Treleaven J
    Bone Marrow Transplant; 1995 Jun; 15(6):853-8. PubMed ID: 7581080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic veno-occlusive disease following bone marrow transplantation.
    Grandt NC
    Oncol Nurs Forum; 1989; 16(6):813-7. PubMed ID: 2687804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation.
    Lee JH; Choi SJ; Lee JH; Kim SE; Park CJ; Chi HS; Lee MS; Lee JS; Kim WK; Lee KH
    Ann Hematol; 2005 May; 84(5):321-30. PubMed ID: 15580502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics.
    Brice K; Valerie B; Claire G; Valerie M; Yves B; Gilles A; Nathalie B
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):135-43. PubMed ID: 17952879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelium and bone marrow transplantation.
    Catani L; Gugliotta L; Vianelli N; Nocentini F; Baravelli S; Bandini G; Cirio TM; Tura S
    Bone Marrow Transplant; 1996 Feb; 17(2):277-80. PubMed ID: 8640179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypercoagulability in patients undergoing autologous or allogeneic BMT for hematological malignancies.
    Catani L; Gugliotta L; Mattioli Belmonte M; Vianelli N; Gherlinzoni F; Miggiano MC; Belardinelli AR; Rosti G; Calori E; Bandini G
    Bone Marrow Transplant; 1993 Sep; 12(3):253-9. PubMed ID: 8241985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation.
    Spitzer TR; Cottler-Fox M; Torrisi J; Cahill R; Greenspan A; Lynch M; Deeg HJ
    Bone Marrow Transplant; 1989 Sep; 4(5):559-65. PubMed ID: 2676044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.